Biocon Biologics launches Yesintek in US

It is one of the first Stelara (ustekinumab) biosimilar market entrants in the country Biocon Biologics has launched YESINTEK (ustekinumab-kfce) which is now available to patients in the US. It is one of the first Stelara (ustekinumab) biosimilar market entrants in the country. YESINTEK is approved for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic [&